Epstein-Barr Virus Latent-infection Membrane Proteins Are Palmitoylated and Raft-associated: Protein 1 Binds to the Cytoskeleton Through TNF Receptor Cytoplasmic Factors

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Apr 11

PMID 11296297

Citations 58

Authors

M Higuchi

K M Izumi

E Kieff

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus encodes integral membrane proteins LMP1 and LMP2A in transformed lymphoblastoid cell lines. We now find that LMP1 associates with the cell cytoskeleton through a tumor necrosis factor receptor-associated factor-interacting domain, most likely mediated by tumor necrosis factor receptor-associated factor 3. LMP1 is palmitoylated, and the transmembrane domains associate with lipid rafts. Mutation of LMP1 cysteine-78 abrogates palmitoylation but does not affect raft association or NF-kappaB or c-Jun N-terminal kinase activation. LMP2A also associates with rafts and is palmitoylated but does not associate with the cell cytoskeleton. The associations of LMP1 and LMP2A with rafts and of LMP1 with the cell cytoskeleton are likely to effect interactions with cell proteins involved in shape, motility, signal transduction, growth, and survival.

Citing Articles

In Silico Modeling and Characterization of Epstein-Barr Virus Latent Membrane Protein 1 Protein.

Salam D, Gunasinghe K, Hwang S, Ginjom I, Chee Wezen X, Rahman T ACS Omega. 2024; 9(50):49422-49431.

PMID: 39713625 PMC: 11656244. DOI: 10.1021/acsomega.4c06868.

Vaccination against Epstein-Barr Latent Membrane Protein 1 Protects against an Epstein-Barr Virus-Associated B Cell Model of Lymphoma.

Soo Hoo W, Higa K, McCormick A Biology (Basel). 2023; 12(7).

PMID: 37508413 PMC: 10376452. DOI: 10.3390/biology12070983.

Targeting Metabolic Vulnerabilities in Epstein-Barr Virus-Driven Proliferative Diseases.

Leung N, Wang L Cancers (Basel). 2023; 15(13).

PMID: 37444521 PMC: 10341354. DOI: 10.3390/cancers15133412.

Thermoplasmonic Vesicle Fusion Reveals Membrane Phase Segregation of Influenza Spike Proteins.

Moreno-Pescador G, Arastoo M, Ruhoff V, Chiantia S, Daniels R, Bendix P Nano Lett. 2023; 23(8):3377-3384.

PMID: 37040311 PMC: 10141563. DOI: 10.1021/acs.nanolett.3c00371.

LMP1 mediates tumorigenesis through persistent epigenetic modifications and PGC1β upregulation.

Chen S, Zhang P, Feng J, Li R, Chen J, Zheng W Oncol Rep. 2023; 49(3).

PMID: 36734290 PMC: 9926514. DOI: 10.3892/or.2023.8490.

References

Moghaddam A, Rosenzweig M, Annis B, Johnson R, Wang F . An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276(5321):2030-3. DOI: 10.1126/science.276.5321.2030. View

Scholle F, Bendt K, Raab-Traub N . Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol. 2000; 74(22):10681-9. PMC: 110942. DOI: 10.1128/jvi.74.22.10681-10689.2000. View

Swart R, Ruf I, Sample J, Longnecker R . Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol. 2000; 74(22):10838-45. PMC: 110964. DOI: 10.1128/jvi.74.22.10838-10845.2000. View

Rousso I, Mixon M, Chen B, Kim P . Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci U S A. 2000; 97(25):13523-5. PMC: 17608. DOI: 10.1073/pnas.240459697. View

Dykstra M, Longnecker R, Pierce S . Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity. 2001; 14(1):57-67. DOI: 10.1016/s1074-7613(01)00089-9. View

Mann K, Staunton D, Thorley-Lawson D . Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol. 1985; 55(3):710-20. PMC: 255052. DOI: 10.1128/JVI.55.3.710-720.1985. View

Wang D, Liebowitz D, Kieff E . An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985; 43(3 Pt 2):831-40. DOI: 10.1016/0092-8674(85)90256-9. View

Liebowitz D, Wang D, Kieff E . Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol. 1986; 58(1):233-7. PMC: 252901. DOI: 10.1128/JVI.58.1.233-237.1986. View

Liebowitz D, Kopan R, Fuchs E, Sample J, Kieff E . An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol. 1987; 7(7):2299-308. PMC: 365360. DOI: 10.1128/mcb.7.7.2299-2308.1987. View

10.

Wang D, Liebowitz D, Kieff E . The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol. 1988; 62(7):2337-46. PMC: 253390. DOI: 10.1128/JVI.62.7.2337-2346.1988. View

11.

Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R . Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988; 62(11):4173-84. PMC: 253849. DOI: 10.1128/JVI.62.11.4173-4184.1988. View

12.

Liebowitz D, Kieff E . Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin. J Virol. 1989; 63(9):4051-4. PMC: 251005. DOI: 10.1128/JVI.63.9.4051-4054.1989. View

13.

Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R . Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990; 64(5):2309-18. PMC: 249392. DOI: 10.1128/JVI.64.5.2309-2318.1990. View

14.

Longnecker R, Kieff E . A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol. 1990; 64(5):2319-26. PMC: 249393. DOI: 10.1128/JVI.64.5.2319-2326.1990. View

15.

Martin J, Sugden B . Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol. 1991; 65(6):3246-58. PMC: 240982. DOI: 10.1128/JVI.65.6.3246-3258.1991. View

16.

Liebowitz D, MANNICK J, Takada K, Kieff E . Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol. 1992; 66(7):4612-6. PMC: 241278. DOI: 10.1128/JVI.66.7.4612-4616.1992. View

17.

Burkhardt A, Bolen J, Kieff E, Longnecker R . An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol. 1992; 66(8):5161-7. PMC: 241398. DOI: 10.1128/JVI.66.8.5161-5167.1992. View

18.

Longnecker R, Miller C, Miao X, Marchini A, Kieff E . The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol. 1992; 66(11):6461-9. PMC: 240138. DOI: 10.1128/JVI.66.11.6461-6469.1992. View

19.

Hammarskjold M, Simurda M . Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol. 1992; 66(11):6496-501. PMC: 240142. DOI: 10.1128/JVI.66.11.6496-6501.1992. View

20.

Laherty C, Hu H, Opipari A, Wang F, Dixit V . The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992; 267(34):24157-60. View